E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 1/9/2024 in the Prospect News Convertibles Daily.

OPKO Health greenshoe lifts 3.75% convertibles to $230 million

By Wendy Van Sickle

Columbus, Ohio, Jan. 9 – Underwriters for OPKO Health Inc.’s 3.75% five-year convertible notes fully exercised their $30 million greenshoe, enlarging the total size of the deal to $230 million, according to a news release.

The company priced $200 million of the convertibles after the market close on Jan. 4 at par with an initial conversion premium of 26.83%, as previously reported.

Pricing came at the cheap end of talk for a coupon of 3.25% to 3.75% and toward the cheap end of talk for an initial conversion premium of 25% to 30%.

J.P. Morgan Securities LLC was bookrunner for the Rule 144A offering, which carries a greenshoe of $30 million.

The notes are non-callable.

They are putable upon a fundamental change.

The company entered into privately negotiated transactions to repurchase for cash $144.4 million in principal of its outstanding 4.5% convertible notes due 2025.

In a concurrent private placement, entities affiliated with OPKO chair and CEO Phillip Frost, OPKO vice-chair and chief technical officer Jane Hsiao and other existing holders will acquire $71.1 million of additional 3.75% convertible notes due 2029 in exchange for $71.1 million of 5% convertible promissory notes, which will include about $5 million in unpaid interest.

Net proceeds will be $221.4 million with the greenshoe.

Approximately $50 million of net proceeds will be used to purchase stock in privately negotiated transactions with the initial purchasers of the notes and $146.3 million and cash on hand will be used to repurchase the 4.5% convertible notes due 2025.

Remaining proceeds will be used for general corporate purposes.

OPKO Health is a Miami-based biopharmaceutical and diagnostics company.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.